Healio Minute (Healio)
Explorez tous les épisodes de Healio Minute
| Date | Titre | Durée | |
|---|---|---|---|
| 07 Dec 2023 | Dermatology Edition: Top Headlines for Week of December 4, 2023 | 00:10:11 | |
In this edition, allergic illnesses in children may be inherited from mothers; addressing needs of Muslim patients in dermatology; YouTube content on topical steroid withdrawal exhibits poor reliability and more. Atopic dermatitis, other allergic illnesses in children may be inherited from mothers Addressing needs of Muslim patients in dermatology YouTube content on topical steroid withdrawal exhibits poor reliability, quality RelabotulinumtoxinA demonstrates rapid onset, durability for frown lines, crow’s feet Puberty, skin of color, weight associated with acne prevalence among adolescents References: Chiesa Fuxench ZC, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.013. El-Banna G, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.4439. McCormick E, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.C7443. Witkam WCAM, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.10.062. | |||
| 29 Dec 2022 | Hematology Oncology Edition: Healio's Top Headlines of 2023 | 00:11:16 | |
In this edition, NCI director announces breast cancer diagnosis, neoadjuvant chemotherapy regimen in pancreatic cancer, gender harassment is in oncology and more. Read the full coverage here: NCI director announces breast cancer diagnosis, says prognosis ‘very favorable’ Neoadjuvant chemotherapy regimen extends survival in pancreatic cancer Survey shows gender harassment is ‘strikingly common’ in oncology Proton pump inhibitor use linked to elevated cancer risk Memorial Sloan Kettering pauses CAR-T clinical trial to investigate patient death References: Katz MHG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2319. Subbiah IM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02574. Tran TH, et al. Abstract 1843. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva. | |||
| 18 Jul 2024 | Lung Cancer Edition: Top Headlines for Week of July 15, 2024 | 00:12:40 | |
In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more. Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC Lung cancer risks persist with e-cigarette use after quitting tobacco smoking COPD, IPF end of life health care use differs from lung cancer Tecentriq combination fails to improve survival in metastatic lung cancer Risk for lung cancer reoccurrence may be associated with OSA-related hypoxemia References: Figueroa Rodriguez F, et al. 0468: CRASH: Cancer reoccurrence is accelerated by episodic hypoxemia. Presented at: SLEEP; June 1-5, 2024; Houston. Kim Y, et al. Association of electronic cigarette use after conventional smoking cessation with lung cancer risk: A nationwide cohort study. Presented at: American Thoracic Society International Conference; May 18-22, 2024; San Diego. Wakelee HA, et al. Abstract LBA8035. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago. | |||
| 17 Jun 2022 | Neurology Edition: Top Headlines for Week of June 13, 2022 | 00:08:53 | |
In this week’s edition, CAR-T ‘robustly effective’ in younger patients with deadly form of brain cancer; SARS-CoV-2 linked to range of neurological diseases; Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability; and more. Read the full coverage here: Steerable microcatheter nets FDA 510(k) clearance for neurologic, peripheral, coronary use CAR-T ‘robustly effective’ in younger patients with deadly form of brain cancer SARS-CoV-2 linked to range of neurological diseases Risk for major adverse CV events elevated with type 2 diabetes, cognitive impairment Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability References: Majzner RG, et al. Abstract CT001. Presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; New Orleans. Klein RS, et al. Neurobiology of COVID-19. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. Cukierman-Yaffe T, et al. J Clin Endocrinol Metab. 2022;doi:10.1210/clinem/dgac200 | |||
| 10 Jan 2023 | Gastroenterology Edition: Top Headlines for Week of January 9, 2023 | 00:11:39 | |
In this edition, groups support CMS policy update on colonoscopy; plant-based food intake and CRC research needed; FDA agrees on pediatric study to develop obefazimod and more. Read the full coverage here: Exact Sciences backs CMS policy update to waive cost-sharing for follow-up colonoscopy Future research needed to investigate link between plant-based food intake, CRC FDA agrees on Abivax’s pediatric study plan to develop obefazimod for children with IBD Roux-en-Y tied to increased risk for hospitalization related to alcohol-use disorder Robotic liver resection for HCC reduced length of hospital stay, ICU admissions References: Benedetto FD, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.5697. Kim J, et al. BMC Medicine. 2022;doi:10.1186/s12916-022-02633-7. Mahmud N, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.6410. Press Release | |||
| 24 Aug 2023 | Dermatology Edition: Top Headlines for Week of August 21, 2023 | 00:10:15 | |
In this edition, M-PDT efficacy similar to isotretinoin in acne vulgaris; Spitz neoplasm diagnosis in adults; immunotherapy treatment shows promise in basal cell carcinoma and more. M-PDT efficacy similar to isotretinoin in acne vulgaris Clinicians should not ‘shy away’ from a Spitz neoplasm diagnosis in adults Novel nonsurgical immunotherapy treatment shows promise in basal cell carcinoma Remibrutinib potential first-in-class oral treatment for chronic spontaneous urticaria Clascoterone cream exhibits significant long-term improvement among children with acne References: Eichenfield LF, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7592. | |||
| 19 Oct 2023 | Dermatology Edition: Top Headlines for Week of October 16, 2023 | 00:08:34 | |
In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more. FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow’s feet Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children FDA approves Zoryve for pediatric psoriasis Colloidal oatmeal, prescription cream comparable in Black children with atopic dermatitis FDA issues complete response letter for lebrikizumab for eczema treatment References: Imam B. Mucocutaneous clinical manifestation of multi-system inflammatory syndrome in children (MIS-C). Presented at: Skin of Color Update; Oct. 6-8, 2023; New York. Lisante TA, et al. J Dermatolog Treat. 2023;doi:10.1080/09546634.2023.2241587. | |||
| 05 Aug 2022 | Breast Cancer Edition: Top Headlines for Week of August 1, 2022 | 00:10:03 | |
In this episode, menopausal hormone therapy is not associated with breast cancer recurrence and mortality; pandemic-related screening declines may result in ‘increased avoidable cancer deaths’; data on pertuzumab regimen in early breast cancer; and more. Read the full coverage here: Menopausal hormone therapy not associated with breast cancer recurrence, mortality Screening declines after pandemic onset may result in ‘increased avoidable cancer deaths’ Updated data show long-term benefit with pertuzumab regimen in early breast cancer Medical financial hardship linked to increased mortality risk among cancer survivors FDA grants priority review to Enhertu for HER2-low metastatic breast cancer References: Cold S, et al. J Natl Cancer Inst. 2022;doi:10.1093/jnci/djac112. Teglia F, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2617. Yabroff KR, et al. J Natl Cancer Inst. 2022;doi:10.1093/jnci/djac044. | |||
| 05 Oct 2023 | Dermatology Edition: Top Headlines for Week of October 2, 2023 | 00:12:26 | |
In this edition, retinoids and OTC products for photoaged skin; fractional lasers show promise in skin cancer prevention; a botanical drug for severe thermal burns and more. Fractional lasers show promise in skin cancer prevention Botanical drug may outperform standard of care for treatment of severe thermal burns 5-fluorouracil cream noninferior to surgery for Bowen’s disease Perifollicular linear projections aid in early diagnosis of facial lentigo maligna References: Ahmady S, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.08.076. McCormick ET, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.2023.NVRN0923. Navarrete-Dechent C, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.07.1036. Sadick N, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7753. | |||
| 26 May 2022 | AMD/Retina Edition: Top Headlines for Week of May 23, 2022 | 00:08:01 | |
Read the full coverage here: In this edition, diet, genetics and family history play role in AMD progression; omega-3 fatty acids may improve vision in dry AMD; long-term dopamine treatment may delay onset of diabetic retinopathy; and more. Diet, genetics and family history play role in AMD progression Omega-3 fatty acids may improve vision in dry AMD Long-term dopamine treatment may delay onset of diabetic retinopathy Anti-VEGF injections decrease aqueous VEGF levels in diabetic retinopathy Novel ERG method aids in monitoring patients with posterior uveitis References: Williams BK. What to do for your patient with early dry AMD. Presented at: American Society of Cataract and Refractive Surgery meeting; April 22-26, 2022; Washington. Prokopiou E, et al. A prospective, randomised, multicenter, double-blind, placebo-controlled study assessing the potential effects of omega-3 fatty acids supplementation on dry age-related macular degeneration and Stargardt disease. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver. Allen RS, et al. Dopamine treatment delays diabetic retinopathy onset in a retrospective study. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver. Mynampati BK, et al. Aqueous levels of VEGF decrease after serial intravitreal injections of anti-VEGF agents in patients with diabetic retinopathy. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver. Than NTT, et al. Flicker ERG findings in posterior uveitis. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver. | |||
| 17 Nov 2022 | Hematology Oncology Edition: Top Headlines for Week of November 14, 2022 | 00:13:13 | |
In this edition, the importance of vaccination after cell therapy, artificial intelligence may help predict cardiotoxicity, experimental breast cancer vaccine generates immune response, and more. Read the full coverage here: Revaccination guidance after cell therapy established for some, ‘evolving’ for others Artificial intelligence may help predict cardiotoxicity in renal cell carcinoma Experimental breast cancer vaccine generates immune response to key tumor protein Cancer cell therapy for melanoma has potential to save ‘thousands’ of lives each year CAR-T regimen ‘should be new standard’ for high-risk B-cell acute lymphoblastic leukemia References: Disis ML, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5143. Sarnaik A, et al. Abstract 789. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston. Saullo JL, et al. The importance of re-vaccination after cellular therapy. Presented at: NCCN 2022 Annual Congress: Hematologic Malignancies; Oct. 14-15, 2022; New York. Wang T, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.01214 Yasin H, et al. Abstract 16. Presented at: International Kidney Cancer Symposium: North America; Nov. 4-5, 2022; Austin, Texas. | |||
| 26 Sep 2024 | Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of September 23, 2024 | 00:11:48 | |
In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more. Blue-collar workers more likely to miss work, quit due to psoriatic arthritis Infliximab biosimilar uptake rapidly increased only after release of a third option National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala Safety checklist compiles clinically important DMARD warnings in one place Guselkumab demonstrates long-term efficacy, safety in psoriasis References: Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1. Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1. Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963. Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1. | |||
| 12 Jan 2023 | Lung Cancer Edition: Top Headlines for Week of January 9, 2023 | 00:11:00 | |
In this edition, addition of tumor treating fields extends OS; atezolizumab-bevacizumab survival rates; screening leads to more stage I, less stage IV disease incidence, and more. Read the full coverage here: Addition of tumor treating fields to standard therapy extends OS in advanced lung cancer Atezolizumab-bevacizumab confers ‘much higher than usual’ survival rates in NSCLC subset Lung cancer screening leads to more stage I, less stage IV disease incidence Anti-TIGIT regimens improve outcomes vs. anti-PD-1 alone in lung cancer subgroup FDA approves adagrasib for certain adults with non-small cell lung cancer References: Johnson ML, et al. Abstract 397600. Presented at: ASCO Plenary Series: December 2022 Session; Dec. 20, 2022. Provencio M, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5959. Vachani A, et al. J Thorac Oncol. 2022;doi:10.1016/j.jtho.2022.08.011. | |||
| 01 Jun 2022 | Neurology Edition: Top Headlines for Week of May 30, 2022 | 00:08:36 | |
In this week’s edition, anxiety, depression worse among older men with vision impairment; emerging therapeutics may improve outcomes in pediatric patients with rare disorders; glioblastoma presents roadblock to successful immunotherapy; and more. Read the full coverage here: MRI findings key pathology markers of 4R-tauopathies Emerging therapeutics may improve outcomes in pediatric patients with rare disorders Together Senior Health launches platform to reduce memory loss in AD, dementia Anxiety, depression worse among older men with vision impairment Glioblastoma presents roadblock to successful immunotherapy References: Carlos AF, et al. Tau histopathological lesion type correlates of structural magnetic resonance imaging and diffusion tensor imaging biomarkers in 4-repeat tauopathies. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. Emrick L, et al. Emerging therapeutics for rare pediatric genetic disorders. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. Gascoyne B, et al. Int Health. 2022;doi:10.1093/inthealth/ihab070 Kumthekar P. AAN year in review: neuro oncology. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. | |||
| 29 Jun 2023 | Neurology Edition: Top Headlines for Week of June 26, 2023 | 00:10:19 | |
In this edition, Leqembi shows benefits in early Alzheimer’s, sex before bed has more positive impact on sleep, clearer guidelines needed on melatonin use in children and more. Read the full coverage here: FDA committee says Leqembi shows benefits in early Alzheimer’s Sex before bed has more positive impact on sleep vs. medication in adults with insomnia Increased education, clearer guidelines needed on melatonin use in children FDA approves Elevidys for pediatric Duchenne muscular dystrophy CMS announces plan for Medicare coverage of approved Alzheimer's drugs References: Kirsch D, et al. How well does sexual activity improve sleep when compared with pharmacologic sleep aids? Presented at: SLEEP; June 3-7, 2023; Indianapolis. Owens J. Navigating the challenges in talking to patients and families about melatonin. Presented at: SLEEP; June 3-7, 2023; Indianapolis. | |||
| 01 Apr 2022 | Coming Soon from Healio: Healio Minute Podcast | 00:00:19 | |
| 25 Apr 2024 | Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of April 22, 2024 | 00:13:32 | |
In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more. FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis Deucravacitinib improves ‘broad range’ of patient-reported psoriatic arthritis outcomes Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure Dactylitis, enthesitis resolution linked to less pain, fatigue in guselkumab-treated PsA References: Gladman DD, et al. J Rheumatol. 2024;doi:10.3899/jrheum.2023-0716. Gossec L, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2024-225531. Rahman P, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06921-8. Strand V, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25333. | |||
| 14 Sep 2022 | Lung Cancer Edition: Top Headlines for Week of September 12, 2022 | 00:12:31 | |
In this edition, germline testing ‘should be considered’ for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more. Read the full coverage here: Germline testing ‘should be considered’ for all patients with lung cancer, data suggest Phase 3 trial of canakinumab for non-small cell lung cancer misses endpoint Sexual dysfunction common among women with lung cancer Younger patients with lung cancer more likely to have advanced disease at diagnosis Sotorasib extends PFS in lung cancer subset References: Florez N, et al. Abstract MA14. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna. Potter A, et al. Abstract OA05. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna. Sorscher S, et al. Abstract 388570. Presented at: ASCO Plenary Series (virtual); Aug. 16, 2022. | |||
| 13 Apr 2022 | AMD/Retina Edition: Top Headlines for Week of April 11, 2022 | 00:07:42 | |
This week, a speaker predicts the AMD epidemic will continue to challenge ophthalmologists; pegcetacoplan results in 18-month reduction in GA lesion growth; interim trial results show efficacy of photo-bio-modulation in dry AMD; and more. Read the full coverage here: AMD epidemic will continue to challenge ophthalmologists Reduction in GA lesion growth continues at 18 months with pegcetacoplan Interim trial results show efficacy of photobiomodulation in dry AMD Ophthalmological manifestations observed in one-third of COVID-19 cases at single center PDT may be effective for choroidal metastasis treatment References: Chew EY. Irving H. Leopold Lecture: Age-related macular degeneration: What have we learned from the age-related eye disease study (AREDS) and AREDS2? Presented at: Wills Eye Conference; March 10-12, 2022; Philadelphia. Romero-Castro RM, et al. Retina. 2022;doi:10.1097/IAE.0000000000003457. Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305. | |||
| 25 Jul 2024 | Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of July 22, 2024 | 00:11:11 | |
In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more. Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription FDA approves biosimilar Pyzchiva for all approved Stelara indications Tofacitinib effective for juvenile idiopathic arthritis through 4 years Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes References: Brunner HI, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2023-225094. Gossec L, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae277. Huang Y, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25378. Ritchlin CT, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06991-8. | |||
| 27 Apr 2023 | Neurology Edition: Top Headlines for Week of April 24, 2023 | 00:10:08 | |
In this edition, trichloroethylene may be ‘invisible’ cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more. Read the full coverage here: Trichloroethylene may be ‘invisible and highly preventable’ cause of Parkinson’s disease DEA petitioned to de-schedule dual orexin receptor antagonist insomnia medications Ravulizumab reduces clinical deterioration in patients with generalized myasthenia gravis FDA places partial clinical hold on initiation of new patients in evobrutinib study FDA advisory committees rule in favor of Rexulti for agitation associated with Alzheimer’s References: Dorsey ER, et al. J Parkinsons Dis. 2023;doi:10.3233?JPD-225047. Mantegazza R, et al. Poster 148: Ravulizumab reduces clinical deteriorations in patients with generalized myasthenia gravis: Results from the CHAMPION MG study. Presented at: Muscular Dystrophy Association Clinical & Scientific Conference; March 19-22, 2023; Dallas. | |||
| 13 Apr 2022 | Lung Cancer Edition: Top Headlines for Week of April 18, 2022 | 00:08:33 | |
In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more. Read the full coverage here: Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint Obesity, pulmonary function may identify need for home oxygen after lung cancer surgery Lung cancer screening less common among those most likely to benefit from it FDA rejects sintilimab with chemotherapy for non-small cell lung cancer Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC References: Nicastri DG, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202103-231OC. Rustagi AS, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.5318. Rajakumar T, et al. npj Precis Oncol. 2022;doi:10.1038/s41698-022-00262-y. | |||
| 24 Nov 2022 | Hematology Oncology Edition: Top Headlines for Week of November 21, 2022 | 00:11:21 | |
In this edition, lung cancer screening critically low across the U.S, first in-human CRISPR test with gene replacement, racial and economic segregation linked to higher cancer mortality rates, and more. Read the full coverage here: Lung cancer screening rates in US ‘simply unacceptable’ First CRISPR-based cell therapy to use gene replacement feasible, safe for solid tumors Racial, economic segregation linked to cancer mortality Onivyde regimen extends OS in metastatic pancreatic ductal adenocarcinoma Immunotherapy a ‘significant improvement’ for treatment of multiple myeloma References: Davies FE, et al. New therapeutic agents for relapsed/refractory multiple myeloma: CAR T and bispecific antibodies. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022. Foy SP, et al. Abstract 1478. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston. Zhang L, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5382. | |||
| 20 Jun 2024 | Lung Cancer Edition: Top Headlines for Week of June 17, 2024 | 00:15:04 | |
In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more. Lung cancer screening program identifies airways disease in previously undiagnosed COPD Positive results in lung cancer show benefits of subcutaneous bispecifics Adagrasib delays progression of pretreated KRAS-mutant lung cancer Durvalumab extends survival in limited-stage small-cell lung cancer Osimertinib delays progression ‘way more’ than hoped in EGFR-mutant lung cancer References: Bernstein E, et al. JCO Precis Oncol. 2024;doi:10.1200/po.23.00447. Leighl NB, et al. Abstract LBA8505. Presented at: ASCO Annual Meeting; May 30–June 3, 2024; Chicago. Ramalingam SS, et al. Abstract LBA4. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago. Seigo MA, et al. Pulmonary comorbidities, respiratory symptoms, and spirometry in a real-world, urban lung cancer screening program. Presented at: American Thoracic Society International Conference; May 17-22, 2024; San Diego. Spigel DR, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago. | |||
| 21 Jul 2022 | AMD/Retina Edition: Top Headlines for Week of July 18, 2022 | 00:06:51 | |
In this edition, Iveric Bio is given exclusive permission to develop, commercialize new formulations of Zimura; subretinal drusenoid deposits linked with cardiovascular disease; subcutaneous elamipretide may improve visual function in geographic atrophy; and more. Read the full coverage here: Iveric Bio given exclusive permission to develop, commercialize new formulations of Zimura Subretinal drusenoid deposits linked with cardiovascular disease Subcutaneous elamipretide may improve visual function in geographic atrophy Combination technique useful for treating myopic traction maculopathy Insufficient treatment common among patients with wet AMD References: Barikian A, et al. Characteristics and outcomes of patients with nAMD managed in US routine clinical practice: An analysis of the IRIS Registry database. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York. Chew FM, et al. Scleral imbrication with combined pars plana vitrectomy and foveal sparing ILM peel as a useful surgical modality in treating myopic traction maculopathy. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York. Heier JS. ReCLAIM-2 study results: A phase 2 study of elamipretide safety & efficacy in geographic atrophy. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York. Thompson RJ, et al. Retina. 2022;doi:10.1097/IAE.0000000000003460. | |||
| 07 Nov 2023 | Prostate Cancer Edition: Top Headlines for Week of November 6, 2023 | 00:10:48 | |
In this edition, multicancer detection tests show promise; lifestyle counseling appointments benefit cancer survivors; use of low-value drugs for patients with cancer, and more. Read the full coverage here: Multicancer detection tests show promise, but questions linger about their accessibility Shared medical appointments for lifestyle counseling benefit cancer survivors Industry payments to physicians spur use of low-value drugs for patients with cancer Study shows link between ultraprocessed foods and mortality risk Radiation oncologist appointed to leadership role at NYU Langone’s Perlmutter Cancer Center References: Mitchell AP, et al. BMJ. 2023;doi:10.1136/bmj-2023-075512. | |||
| 11 Jul 2024 | DME/Retina Edition: Top Headlines for Week of July 8, 2024 | 00:10:22 | |
In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. FDA approves Vabysmo prefilled syringe for retinal diseases VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates FDA approves Eylea biosimilar FYB203/Ahzantive VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study ANI Pharmaceuticals to acquire Alimera Sciences References: Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah. Healio Interviews Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market. | |||
| 15 May 2024 | Lung Cancer Edition: Top Headlines for Week of May 13, 2024 | 00:13:04 | |
In this edition, smoking cessation support uptake at lung cancer screenings, glecirasib may deliver ‘efficacy and tolerability advantages’ and more. Uptake of smoking cessation support high when offered at lung cancer screening Glecirasib may deliver ‘efficacy and tolerability advantages’ for KRAS-mutant lung cancer ‘Substantial geographic disparities’ worsening in cancer clinical trial availability Deployed military personnel have increased silica in lung tissue FDA approves Alecensa for certain patients with ALK-positive lung cancer References: Lowers H, et al. Int J Environ Res Public Health. 2024;doi:10.3390/ijerph21010091.Press Release Murray RL, et al. Eur Respir J. 2024;doi:10.1183/13993003.01768-2023. Sekar RR, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2024.10162. Shi Y, et al. Abstract 468214. Presented at: ASCO Plenary Series; April 30, 2024. | |||
| 07 Jul 2022 | Neurology Edition: Top Headlines for Week of July 4, 2022 | 00:09:47 | |
In this week’s edition, women are less likely than men to return to work after large vessel occlusion stroke; cognitive impairment, headaches and CVD are more common in former college football players; veterans, providers support the addition of integrative medicine for chronic headaches; and more. Read the full coverage here: Women less likely than men to return to work after large vessel occlusion stroke Cognitive impairment, headaches, CVD more common in former college football players Veterans, providers support addition of integrative medicine for chronic headaches New blood biomarker may lead to early diagnosis of frontotemporal dementia Phase 2 trial shows promising results for oral Parkinson’s treatment References: Hahn M, et al. Stroke. 2022;doi:10.1161/STROKEAHA.121.037386. Phelps A, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8775. | |||
| 07 Apr 2022 | Neurology Edition: Top Headlines for Week of April 4, 2022 | 00:09:58 | |
In this week's addition, the FDA approval of a transdermal patch to treat Alzheimer’s-related dementia; the link between daily napping among older adults and an increased risk for Alzheimer’s disease; an oral treatment for Parkinson’s demonstrated positive phase 2 results; and more. Read the full coverage here: FDA approves transdermal patch to treat Alzheimer’s-related dementia Daily napping among older adults linked to a 40% higher risk for Alzheimer’s disease Oral treatment for Parkinson’s shows positive phase 2 results Sleep academy warns lawmakers about health risks of permanent daylight saving time AAN: Medication, exercise more beneficial than stent in preventing stroke References: Li P, et al. Alzheimers Dement. 2022;doi:10.1002/alz.12636. Turan TN, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200030. | |||
| 22 Sep 2022 | Neurology Edition: Top Headlines for Week of September 19, 2022 | 00:09:42 | |
In this edition, FDA votes to support approval of ALS therapy; partnership offers military veterans access to psychedelics; epidural steroid injections as alternate pain management options and more. Read the full coverage here: FDA advisory committee votes to support approval of ALS therapy Partnership offers military veterans access to psychedelics at home, abroad Epidural steroid injection an alternate pain management option Ketamine may be effective in treating children with ADNP syndrome FDA accepts new drug application for Rett syndrome treatment References: Christo PJ. Landscape of wonders: Injections, nerve blocks, pumps and neuromodulation. Presented at: PAINWeek; Las Vegas; Sept. 9-12, 2022. Kolevzon A, et al. HGG Adv. 2022;doi:10.1016/j.xhgg.2022.100138. | |||
| 01 Jun 2023 | Leukemia Edition: Top Headlines for Week of May 29, 2023 | 00:11:41 | |
In this edition, cross-border partnership takes on survival gap for children with leukemia; ‘paradigm shift’ in transfusion-dependent myelodysplastic syndrome; FDA approves Ayvakit for mastocytosis and more. Cross-border partnership takes on ‘huge survival gap’ among children with leukemia Luspatercept ‘a paradigm shift’ in transfusion-dependent myelodysplastic syndrome FDA approves Ayvakit for indolent systemic mastocytosis Novel leukemia treatment signals ‘new era in CAR T-cell therapy’ Functional precision medicine-guided approach benefits pediatric patients with cancer References: Acanda de la Rocha AM, et al. Abstract LB358. Presented at: American Association of Cancer Research Annual Meeting; April 14-19, 2023; Orlando. Appelbaum J, et al. Abstract 3092. Presented at: American Society of Gene & Cell Therapy Annual Meeting; May 16-20, 2023; Los Angeles. Aristizabal P, et al. Abstract 1502. Presented at: ASCO Annual Meeting; June 2-6, 2022; Chicago. Garcia-Manero G, et al. Abstract 7003. Scheduled for presentation at: ASCO Annual Meeting; June 2-6, 2022; Chicago. | |||
| 23 Nov 2022 | Gastroenterology Edition: Top Headlines for Week of November 21, 2022 | 00:12:42 | |
In this edition, best practice statements for celiac disease; older patients with IBD at risk for treatment failure with vedolizumab; Follow-up surveillance for post-colonoscopy CRC and more. Read the full coverage here: AGA releases 10 best practice statements for management of refractory celiac disease Older patients with IBD at higher risk for treatment failure with vedolizumab Follow-up surveillance within 5 years may detect post-colonoscopy CRC Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks PLX065 reduces liver fat content, prevents worsening of fibrosis in NASH References: Degasperi E, et al. Extension of bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the Italian multicenter study (HEP4Di). Presented at: The Liver Meeting; Nov. 4-8, 2022; Washington (hybrid). Green PHR, et al. Gastroenterology. 2022;doi:10.1053/j.gastro.2022.07.086 Harrison SA, et al. PLX065 (deuterium-stabilized r-enantiomer of pioglitazone) reduces liver fat content and improves liver histology without PPAR gamma-mediated side effects in patients with NASH: Analysis of a 36-week placebo-controlled phase 2 trial (DESTINY1). Presented at: The Liver Meeting; Nov. 4-8, 2022; Washington (hybrid meeting). Imperiale TF, et al. Abstract S245: Risk factors for 5-year post-colonoscopy colorectal cancers Singh S, et al. JAMA Netw Open. 2022;doi: 10.1001/jamanetworkopen.2022.34200. | |||
| 30 Mar 2023 | Leukemia Edition: Top Headlines for Week of March 27, 2023 | 00:14:46 | |
In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatric cancer and more. Optimal antibiotics timing ‘likely differs’ among inpatients with cancer, neutropenic fever Inflammation levels linked to survival in acute myeloid leukemia Dexrazoxane confers long-term cardioprotection after anthracyclines for pediatric cancer Menin inhibitor produces high response rates in certain acute leukemia subtypes Tisa-cel CAR-T reinfusion lacks durability for younger patients with B-cell ALL References: Chow EJ, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02423. Issa GC, et al. Nature. 2023;doi:10.1038/s41586-023-05812-3. Krupski C, et al. Abstract LBA4. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando. Lasry A, et al. Nat Cancer. 2022;doi:10.1038/s43018-022-00480-0. | |||
| 19 May 2022 | Neurology Edition: Top Headlines for Week of May 16, 2022 | 00:08:04 | |
In this week’s edition, childhood sexual and emotional abuse increases the risk for multiple sclerosis in women; fentanyl-related cardiac arrest is linked to worse neurological outcomes; Black patients with MS have a higher rate of disability compared with their white counterparts; and more. Read the full coverage here: Childhood sexual, emotional abuse increases multiple sclerosis risk in women Fentanyl-related cardiac arrest linked to worse neurological injury, outcomes Black MS patients have higher rate of disability than white counterparts Brain stimulation software receives FDA approval for use in Parkinson’s disease Seizure frequency, poor quality of life risk factors for depression in epilepsy patients References: Eid K, et al. J Neurol Neurosurg Psychiatry. 2022;doi:10.1136/jnnp-2021-328700. Otero M, et al. Neurological injury and outcomes in fentanyl-related cardiac arrest. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. Dykes E, et al. Health disparities in African American patients with multiple sclerosis: a retrospective chart-review study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. Syed M, et al. Factors associated with depression in epilepsy patients: a population-based study in the Detroit metropolitan area. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. | |||
| 27 Jul 2023 | Dermatology Edition: Top Headlines for Week of July 24, 2023 | 00:10:10 | |
In this edition, lack of sunless tanner education may cause confusion; intralesional HPV vaccine may clear recalcitrant warts; Ilumetri improves well-being of patients with plaque psoriasis and more. Lack of sunless tanner education may cause diagnostic confusion, UV exposure Intralesional HPV vaccine may clear recalcitrant warts New, positive results show Ilumetri improves well-being of patients with plaque psoriasis AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis TikTok ‘excellent opportunity’ for dermatologists to create skin of color content References: Campbell JR, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7061. | |||
| 03 Aug 2023 | Leukemia Edition: Top Headlines for Week of July 31, 2023 | 00:11:39 | |
In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more. FDA approves Vanflyta for newly diagnosed acute myeloid leukemia VIDEO: Liso-cel could have ‘best shot’ at remission for double refractory CLL Community affluence, insurance mediate CV mortality among Black, white cancer survivors VIDEO: MOLTO study probes combination therapy in Richter syndrome Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome References: ASCO Annual Meeting | |||
| 10 Nov 2022 | Hematology Oncology Edition: Top Headlines for Week of November 7, 2022 | 00:13:35 | |
In this edition, FDA approves Tecvayli for multiple myeloma, radiation and hormone therapy slows progression of prostate cancer, and more. Read the full coverage here: FDA approves Tecvayli for advanced multiple myeloma Adding radiation to hormone therapy slows progression of oligometastatic prostate cancer Use of cannabis during cancer treatment may have ‘under-appreciated’ financial impact Older cancer survivors at higher risk for bone fracture Machine-learning approach using step counts predicts hospitalization during radiotherapy References: Chino F, et al. Abstract 24. Presented at: ASCO Quality Care Symposium; Sept. 30-Oct. 1, 2022; Chicago. Friesner I, et al. Abstract 132. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; New Orleans. Rees-Punia E, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5153. Tang C, et al. Abstract LBA 05. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; San Antonio. | |||
| 01 Jul 2022 | Breast Cancer Edition: Top Headlines for Week of June 27, 2022 | 00:13:43 | |
In this edition, late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic; chemicals found in hair products increase viability of breast cancer cells in Black women; continued CDK 4/6 inhibition after breast cancer progression may benefit some patients; and more. Read the full coverage here: Late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic Chemicals found in hair products increase viability of breast cancer cells in Black women Continued CDK 4/6 inhibition after breast cancer progression may benefit some patients Some older women with luminal A breast cancer can safely forgo radiotherapy, study shows Sacituzumab govitecan significantly extends PFS in advanced breast cancer subset References: Zhou JZ, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2021.48581. Trevino L, et al. RF22 | PMON05. Presented at: ENDO Annual Meeting; June 11-14, 2022; Atlanta (hybrid meeting). Kalinsky K, et al. Abstract LBA1004. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Source: Whelan TJ, et al. Abstract LBA501. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Rugo HS, et al. Abstract LBA1001. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. | |||
| 08 Dec 2022 | Neurology Edition: Top Headlines for Week of December 5, 2022 | 00:12:43 | |
In this edition, foslevodopa-foscarbidopa improves motor symptoms in advanced PD, posterior surgery for treating cervical radiculopathy, Tysabri favored over IV in patients with relapsing-remitting MS and more. Read the full coverage here: Continuous subcutaneous foslevodopa-foscarbidopa improves motor symptoms in advanced PD Posterior surgery noninferior to anterior for treating cervical radiculopathy Subcutaneous delivery of Tysabri favored over IV in patients with relapsing-remitting MS NeuroLogica receives FDA clearance for multiuse imaging tool Vumerity effective over 96 weeks in patients with relapsing-remitting MS References: Broekema AEH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.4208. Gold R, et al. SISTER – subcutaneous: non-interventional, observational, prospective, German multicenter, open-label study over 12-months for Tysabri patient preference – experience from real world – preliminary results of the 1st interim analysis. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam. Singer BA, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam. Soileau MJ, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00400-8. | |||
| 07 Oct 2022 | Breast Cancer Edition: Top Headlines for Week of October 3, 2022 | 00:12:24 | |
In this episode, FDA approves Rolvedon to reduce infection incidence; women want more education on sexual health during treatment; abemaciclib regimen shows further signs of benefit and more. Read the full coverage here: FDA approves Rolvedon to reduce infection incidence when taking certain anticancer drugs Women with breast cancer want more education on sexual health during treatment Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup Cancer-related fatigue may impact balance after breast cancer treatment Chronic inflammation linked to cognitive difficulties among older breast cancer survivors References: Carroll JE, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.00406. Goetz MP, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris. Huynh V, et al. Ann Surg Oncol. 2022;doi:10.1245/s10434-022-12126-7. Wechsler S, et al. Rehab Oncol. 2022;doi:10.1097/01.REO.0000000000000308. | |||
| 09 Nov 2022 | Gastroenterology Edition: Top Headlines for Week of November 7, 2022 | 00:10:46 | |
In this edition, Achalasia is associated with higher esophageal cancer risk; FDA rejects bulevirtide for hepatitis D and liver disease; real-world data on colonoscopy prep and more. Read the full coverage here: Achalasia associated with five-fold higher risk for esophageal cancer FDA rejects Gilead’s bulevirtide for hepatitis D, compensated liver disease Polyethylene glycol, ascorbic acid cleanse highly effective for colonoscopy prep Distal cap-assisted endoscopic mucosal resection safe, effective for fibrotic polyps FDA backs EndoStim’s neurostimulation implant for GERD control References: Arieira C, et al. Abstract S589: One-Liter Polyethylene Glycol + Ascorbic Acid Bowel Preparation Delivers High Levels of Adequate and High-Quality Bowel Cleansing for Colonoscopy. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting). Douglas SR, et al. Abstract S130: Distal Cap-Assisted Endoscopic Mucosal Resection Is a Safe and Effective Technique for Resection of Non-Lifting or Adherent Colorectal Polyps: An International, Multicenter, Retrospective Study. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting). Low EE, et al. Abstract S388: Risk of esophageal cancer in achalasia: A matched cohort study utilizing the veterans affairs achalasia cohort (VA-AC). Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting). | |||
| 04 Aug 2022 | Neurology Edition: Top Headlines for Week of August 1, 2022 | 00:09:39 | |
In this edition, temperature-controlled mattresses and pillows improve sleep; how overturning Roe v. Wade affects the field of neurology; college students’ cognition altered by changing sleep patterns and more. Read the full coverage here: Temperature-controlled mattress, pillow improve sleep onset, quality Decision to overturn Roe v. Wade will ‘undoubtedly’ affect those in the field of neurology Changing sleep patterns affect cognition in college students FDA grants tentative approval for daytime sleepiness treatment Study shows people with migraines have lower risk for sleep apnea References: Costa A, et al. Daily patterns of sleep and metacognition in college students. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C. Gruenthal E, et al. Polysomnographic biomarkers of sleep disruption and sleep disordered breathing in migraine: A large matched case control clinical registry-based study. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C. Haghayegh S, et al. J Sleep Res. 2022;doi:10.1111/jsr.13662. LaHue SC, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2347. | |||
| 08 Aug 2024 | DME/Retina Edition: Top Headlines for Week of August 5, 2024 | 00:11:23 | |
In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more. Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years References: Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm. Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm. Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808. Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm. | |||
| 15 Jun 2023 | Leukemia Edition: Top Headlines for Week of June 12, 2023 | 00:13:50 | |
In this edition, prior authorization linked delay in prescription fills; disparities in access to specialized cancer centers; ‘new potential treatment option’ for advanced chronic lymphocytic leukemia and more. Prior authorization policies linked to 2-week delay in anticancer-drug prescription fills AYAs with rare leukemia face disparities in access to specialized cancer centers Liso-cel CAR-T ‘new potential treatment option’ for advanced chronic lymphocytic leukemia Benefits of ivosidenib regimen for IDH1-mutant AML increase with longer follow-up Childhood cancer survivors at increased risk for sleep concerns decades after diagnosis References: Daniel LC. Sleep in long-term childhood cancer survivors compared to siblings: A report from the Childhood Cancer Survivor Study. Presented at: SLEEP; June 3-7, 2023; Indianapolis. De Botton S, et al. Abstract 7012. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Kyle MA, et al. Abstract 1504. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Muffly L, et al. Abstract 7008. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Siddiqi T, et al. Abstract 7501. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. | |||
| 06 Oct 2022 | Neurology Edition: Top Headlines for Week of October 3, 2022 | 00:13:10 | |
In this edition, lecanemab study shows reduction in clinical decline for early AD; multimorbidity associated with increased risk for dementia, Crenezumab not effective in treating Alzheimer's disease and more. Read the full coverage here: Phase 3 study of lecanemab shows reduction in clinical decline in patients with early AD Multimorbidity associated with increased risk for dementia Crenezumab not effective in treating Alzheimer's disease FDA approves macrocyclic GBCA for contrast-enhanced MRI Healthy habits in midlife may help delay onset of cognitive decline References: Calvin CM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32124. Ostrowitzki S, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2909. Small G. What’s preventing us from preventing dementia? Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas. | |||
| 30 Nov 2022 | Hematology Oncology Edition: Top Headlines for Week of November 28, 2022 | 00:13:13 | |
In this edition, disparities among women in the surgical workforce, GSK withdraws belantamab mafodotin from US market, risk for lymphoma low after postmastectomy reconstruction, and more. Read the full coverage here: More women surgeon scientists receive NIH funding than in 2010, yet gender gaps remain GSK to withdraw multiple myeloma therapy from US market Risk for lymphoma after postmastectomy breast implant reconstruction ‘still extremely low’ Differences observed in adverse events of antibody-drug conjugates FDA approves Hemgenix as first gene therapy for treatment of hemophilia B References: Kinslow CJ, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.43396. Saif A, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.5157 | |||
| 10 Aug 2023 | Dermatology Edition: Top Headlines for Week of August 7, 2023 | 00:10:49 | |
In this edition, nonalcoholic muscadine wine may improve aging skin; atopic disease risk increases in sexually diverse patients; AI doubles diagnostic accuracy among patients with skin of color and more. Nonalcoholic muscadine wine may improve aging skin in older women Atopic disease risk increases in sexually diverse patients AI doubles diagnostic accuracy of skin conditions among patients with skin of color Post-acne scarring should be treated as primary skin condition Histologic margin status can help predict lentigo maligna melanoma recurrence References: Christman L. Dealcoholized muscadine wine improved skin health, reduced oxidative stress and inflammation in women in a randomized controlled trial. Presented at: NUTRITION; July 22-25, 2023; Boston. | |||
| 01 Dec 2022 | Neurology Edition: Top Headlines for Week of November 28, 2022 | 00:11:43 | |
In this edition, risk factors linked to PD, digital brain health platform offers dementia risk assessment, Klotho protein levels linked to Alzheimer's and more. Read the full coverage here: Tremor, restless legs syndrome, schizophrenia among risk factors linked to PD Digital brain health platform offers rapid, accurate assessment of dementia risk Klotho protein levels linked to Alzheimer's, cognitive decline, amyloid and tau burden Body temperature irrigation for chronic subdural hematoma should be ‘standard of care’ FDA requests additional information, extends goal date for application of MS treatment References: Bartley A, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.4133. Grøntvedt GR, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.43232. Press Conference Schrag A et al. JAMA Neurology. 2022;doi:10.1001/jamaneurol.2022.3902. | |||
| 20 Apr 2022 | AMD/Retina Edition: Top Headlines for Week of April 18, 2022 | 00:08:45 | |
In this edition, digital imaging and AI advance investigation of systemic disease through the retina; handheld retinal imaging devices may have utility in screening; Xipere launches in the US; and more. Read the full coverage here: Digital imaging, AI advance investigation of systemic disease through the retina No additional visual benefit seen with nesvacumab-aflibercept combination in DME Soft drusen, subretinal drusenoid deposits may be separate diseases leading to AMD Handheld retinal imaging devices may have utility in screening References: Healio Interviews Brown DM, et al. Retina. 2022;doi:10.1097/IAE.0000000000003441. Thomson RJ, et al. Retina. 2022;doi:10.1097/IAE.0000000000003460. Salongcay RP, et al. Ophthalmol Retina. 2022;doi:10.1016/j.oret.2022.03.002 | |||
| 22 Aug 2024 | Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of August 19, 2024 | 00:11:18 | |
In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more. Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations Opioid use has fallen 15% annually since 2014 in autoimmune rheumatic disease Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk S100 protein levels predict abatacept response in juvenile idiopathic arthritis Izokibep shows early promise in hidradenitis suppurativa References: Brunner HI, et al. Arthritis Res Ther. 2024;doi:10.1186/s13075-024-03347-0. Falasinnu T, et al. Lancet Rheumatol. 2024;doi:10.1016/S2665-9913(24)00120-6. Tsai SHL, et al. J Am Acad Dermatol. 2024;doi:10.1016/j.jaad.2024.07.1473. | |||
| 19 Sep 2024 | Lung Cancer Edition: Top Headlines for Week of September 16, 2024 | 00:13:55 | |
In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more. FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’ Perioperative nivolumab improves outcomes in resectable NSCLC Despite progress, barriers to lung cancer biomarker testing persist Atezolizumab regimen ‘merits further study’ for unresectable NSCLC References: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897. Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. | |||
| 07 Sep 2023 | Dermatology Edition: Top Headlines for Week of September 4, 2023 | 00:11:30 | |
In this edition, nearly $1 million in grants to aid diversity, equity, inclusion research; topical halcinonide may benefit patients with psoriasis; Asian patients may experience earlier mycosis fungoides diagnosis and more. Nearly $1 million in grants to aid dermatology research in diversity, equity, inclusion Topical halcinonide may benefit patients with psoriasis with inadequate biologics response Asian patients may experience earlier mycosis fungoides diagnosis, better outcomes COVID-19 pandemic led to delayed melanoma diagnoses, more advanced tumors Dupilumab use correlates with S. aureus reductions, atopic dermatitis improvements References: Bagel J, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.6830. | |||
| 27 Jun 2024 | Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of June 24, 2024 | 00:10:14 | |
In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more. Extensive psoriasis, IBD history predict difficult-to-treat psoriatic arthritis Targeted psoriatic arthritis therapies demonstrate low risk for serious infection VIDEO: Dermatologists, rheumatologists share care in psoriasis, psoriatic arthritis Patients with arthritis at higher risk for poor nutrition regardless of function FDA approves Rinvoq for JIA, psoriatic arthritis in children aged 2 years and older References: Bastard L, et al. RMD Open. 2024;doi:10.1136/rmdopen-2023-003865. Bennett R, et al. Sci Rep. 2024;doi:10.1038/s41598-024-58370-7. Husni ME. Update in the treatment of psoriatic arthritis. Presented at: Medical Dermatology Therapy Update III; May 29-31, 2024; Cleveland. Vassilakis KD, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae263. | |||
| 15 Aug 2024 | Lung Cancer Edition: Top Headlines for Week of August 12, 2024 | 00:15:14 | |
In this edition, low education level raises follow-up risk in screening program, screening judgement strongly influenced by clinicians and more. Low education level raises risk for loss to follow-up in lung cancer screening program Lung cancer screening judgement strongly influenced by clinicians Occupational benzene exposure heightens lung cancer likelihood Chemotherapy plus nintedanib has ‘promising’ efficacy in small cell lung cancer with IPF Blood biomarker identifying benign lung nodules performs well across subgroups References: Ikeda S, et al. Ann Am Thorac Soc. 2024;doi:10.1513/AnnalsATS.202311-941OC. Long KJ, et al. CHEST. 2023;doi:10.1016/j.chest.2023.06.037. Mugutso E, et al. Ann Am Thorac Soc. 2023;doi:10.1513/AnnalsATS.202304-348RL. Núñez ER, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202301-0155OC. Wan W, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202306-0942OC. | |||
| 14 Mar 2024 | Lung Cancer Edition: Top Headlines for Week of March 11, 2024 | 00:12:07 | |
In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more. Race identified as risk factor for VTE after pulmonary resection for lung cancer FDA approves Rybrevant for treatment of non-small cell lung cancer Behavioral health disorders have a ‘big impact’ on cancer surgery outcomes Optimizing immunotherapy, biomarker testing vital to progress in lung cancer treatment FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer References: Axtell AL, et al. Ann Thorac Surg. 2024;doi:10.1016/j.athoracsur.2024.01.005. Katayama ES, et al. J Am Coll Surgeons. 2024;doi:10.1097/XCS.0000000000000954. | |||
| 08 Jun 2022 | Lung Cancer Edition: Top Headlines for Week of June 6, 2022 | 00:10:34 | |
In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more. Read the full coverage here: AYA cancer survivors at higher risk for death due to second primary cancers Radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint As proton beam therapy use for cancer increased, ‘so did the racial disparity in receipt’ Entrectinib induces durable, intracranial responses in NTRK fusion-positive solid tumors References: Sung H, et al. J Natl Cancer Inst. 2022;doi:10,1093/jnci/djac091. Louie AV, et al. JAMA Oncol. 2022:doi:10.1001/jamaoncol.2021.7664. Nogueira LM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8970. Demetri GD, et al. Clin Cancer Res. 2022;doi:10.1158/1078-0432.CCR-21-3597. | |||
| 11 May 2023 | Lung Cancer Edition: Top Headlines for Week of May 8, 2023 | 00:12:06 | |
In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more. Read the full coverage here: Tumor mutational burden may be linked to immunotherapy response in advanced cancers Perioperative toripalimab regimen extends EFS in resectable stage III NSCLC Phase 3 study of lung cancer regimen designed to be a model for increasing trial diversity Smoking cessation before lung cancer diagnosis significantly reduces excess mortality risk Pembrolizumab active in diffuse malignant peritoneal mesothelioma References: Aggarwal C, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11181. Lu S, et al. Abstract 425126. Presented at: ASCO Plenary Series: April 2023 Session; April 20, 2023. Marmarelis ME, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2526. Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients (NCI press release). Published April 12, 2023. Accessed April 12, 2023. Wang X, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11966. | |||
| 21 Dec 2023 | Dermatology Edition: Top Headlines for Week of December 18, 2023 | 00:08:09 | |
In this edition, an advocacy group petitions the FDA for stronger safety warnings for Botox, melanoma regression is associated with improved prognosis and more. Advocacy group petitions FDA for stronger safety warnings for Botox, related drugs Melanoma regression associated with improved prognosis Phase 4 results show Vtama cream efficacious in head, neck plaque psoriasis Isotretinoin not associated with increased risk for suicide, psychiatric conditions Tape strips may identify hidradenitis suppurativa in lesional, nonlesional skin References: Navrazhina K, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.048. Tan NKW, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.4579. Wagner NB, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.040. | |||
| 25 Aug 2022 | Neurology Edition: Top Headlines for Week of August 22, 2022 | 00:09:06 | |
In this edition, leisure activities may lower risk for Alzheimer's disease and dementia; most common long COVID symptoms include fatigue and headache; ‘life-changing’ app-based digital therapeutic for tinnitus and more. Read the full coverage here: Leisure activities may lower risk for Alzheimer's disease, dementia Fatigue, headache most common long COVID symptoms Personalized, app-based digital therapeutic for tinnitus ‘life-changing’ NIH to fund development, testing of robots to aid in Alzheimer's disease care AI algorithm detects brain abnormalities, could help treat epilepsy References: Chen AK, et al. Brain Behav Immun. 2022;doi:10.1016/j.bbih.2022.100491 Searchfield GD, et al. Front Neurol. 2022;doi:10.3389/fneur.2022.958730 Spitzer H, et al. Brain. 2022;doi:10.1093/brain/awac224 Su S, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200929 | |||
| 31 Aug 2022 | AMD/Retina Edition: Top Headlines for Week of August 29, 2022 | 00:07:33 | |
In this edition, macular retinal nerve fiber layer thickness linked with cognitive decline; FDA approves Lucentis biosimilar; advanced visual field loss risk higher after glaucoma diagnosis in Black patients; and more. Association found between macular retinal nerve fiber layer thickness, cognitive decline FDA approves Cimerli as interchangeable biosimilar to Lucentis Black patients have higher risk for advanced visual field loss after glaucoma diagnosis iStent infinite cleared by FDA Alcon to acquire Aerie Pharmaceuticals References: Kang JH, et al. Transl Vis Sci Technol. 2022;doi:10.1167/tvst.11.7.21. Kim HM, et al. JAMA Ophthalmol. 2022;doi:10.1001/jamaophthalmol.2022.1563. | |||
| 08 Jun 2023 | Lung Cancer Edition: Top Headlines for Week of June 5, 2023 | 00:13:24 | |
In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more. Read the full coverage here: Surgery confers higher 5-year survival rates than radiotherapy in early-stage lung cancer First-line combination extends PFS in lung cancer subgroup Pembrolizumab improves outcomes in early-stage resectable lung cancer Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC Severe myelosuppression common after chemotherapy for small cell lung cancer References: Hart L, et al. Cancer Med. 2023;doi:10.1002/cam4.5738. Kanda S, et al. Abstract LBA9009. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Udelsman B, et al. Abstract 275. Presented at: American Association for Thoracic Surgery Annual Meeting; May 6-9, 2023; Los Angeles. Wakelee H, et al. Abstract LBA100. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. | |||
| 28 Jul 2022 | Neurology Edition: Top Headlines for Week of July 25, 2022 | 00:08:31 | |
In this week’s edition, a Labcorp blood test identifies signs of neurodegenerative disease; the FDA approves an oral treatment for partial seizures in teens; ketamine shows efficacy in epilepsy; and more. Read the full coverage here: Labcorp blood test identifies signs of neurodegenerative disease FDA approves oral treatment for partial seizures in patients aged 16 years and older Ketamine effective treatment for neonatal, pediatric epilepsy FDA places hold on phase 2/3 clinical trial of stroke therapy Hypertension, obesity, physical inactivity among highest risk factors for dementia References: Jacobwitz M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200889. Lee M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.19672. | |||
| 11 Aug 2022 | Lung Cancer Edition: Top Headlines for Week of August 8, 2022 | 00:11:42 | |
In this edition, lung cancer risk is high among smokers for whom screening is not recommended; the role of circulating tumor DNA in lung cancer detection and treatment is 'exciting' for field; a subset of patients with lung cancer have poor response to COVID-19 vaccines, and more. Read the full coverage here: Lung cancer risk high among smokers for whom screening is not recommended Role of circulating tumor DNA in lung cancer detection, treatment 'exciting' for field Subset of patients with lung cancer have poor response to COVID-19 vaccines Low area-level income, education linked to higher odds of late-stage lung cancer diagnosis Phase 3 trial of Onivyde for small cell lung cancer misses endpoint References: Faselis C, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2952. Gupta A, et al. Cancer. 2022;doi:10.1002/cncr.34327. Healio Interview Valanparambil RM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02986. | |||
| 22 Dec 2022 | Hematology Oncology Edition: Top Headlines for Week of December 19, 2022 | 00:11:55 | |
In this edition, cancer and COVID-19 increase risk for thromboembolism, glofitamab shows curative potential in lymphoma, efgartigimod improves platelet counts, and more. Read the full coverage here: Biomarkers predict thromboembolism risk, mortality among people with cancer, COVID-19 Glofitamab shows ‘curative potential’ in relapsed/refractory diffuse large B-cell lymphoma Efgartigimod confers rapid improvement in platelet counts in immune thrombocytopenia Odronextamab ‘potentially curative’ in third-line setting for follicular lymphoma Dana-Farber professor receives William Dameshek Prize for multiple myeloma research References: Broome CM, et al. Abstract 3. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Hutchings M, et al. Abstract 441. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Khorana AA, et al. Abstract 136. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Kim TM, et al. Abstract 949. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. | |||
| 16 Feb 2023 | Leukemia Edition: Top Headlines for Week of February 13, 2023 | 00:13:49 | |
In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more. Novel T-cell therapy effective against common viruses after stem cell transplantation FDA approves Brukinsa for chronic lymphocytic leukemia, small lymphocytic lymphoma Review of meeting abstracts shows toxicity reporting inconsistent, incomplete Cumulative anesthesia exposure linked to impaired neurocognitive function in pediatric ALL Imetelstat confers durable transfusion independence in lower-risk myelodysplastic syndrome References: Alexander S, et al. Abstract 901. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Chin-Yee B, et al. Abstract 129. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2013; New Orleans. Pfeiffer T, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2415. | |||
| 13 Apr 2023 | Leukemia Edition: Top Headlines for Week of April 10, 2023 | 00:15:11 | |
In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and more. DNA sequencing could identify patients with AML at high risk for relapse after HSCT Review highlights major advances, continuing challenges in chronic lymphocytic leukemia FDA advisory panel backs polatuzumab vedotin-piiq benefit-risk profile in first-line DLBCL CAR T cells improve quality of life for majority of recipients Community physicians play essential role in long-term care after CAR-T References: Dillon LW, et al. JAMA. 2023;doi:10.1001/jama.2023.1363. Healio Interviews Johnson PC, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2022009117. | |||
| 27 Oct 2022 | Neurology Edition: Top Headlines for Week of October 24, 2022 | 00:11:09 | |
In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more. Read the full coverage here: Evaluate headache characteristics to classify as migraine FDA grants breakthrough device designation for brain implant technology New genetic engineering company aims to develop neuroactive compounds from plants, fungi Angiotensin receptor blocker therapy associated with decreased incidence of epilepsy Theranica announces positive results from clinical trial for migraine treatment device References: Diamond M. Migraine, chronic migraine and medication overuse headache: Where are we today? Presented at: PAINWeek; Sept. 6-9, 2022; Las Vegas Doege C, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3413. | |||
| 04 May 2022 | Neurology Edition: Top Headlines for Week of May 2, 2022 | 00:10:24 | |
In this week’s edition, risk for cognitive decline is associated with older COVID-19 survivors; a study validates an FDA-approved blood test for traumatic brain injury; and more. Read the full coverage here: Risk for cognitive decline associated with older COVID-19 survivors Study validates FDA-approved blood test for traumatic brain injury VA hospital telestroke networks improve treatment, lower ED transfer rate Lower left atrial function associated with higher risk for dementia Rates of neurological events higher with SARS-CoV-2 infection than with COVID-19 vaccine References: Liu YH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.0461. Papa L, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.1302. Lyerly M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200143. | |||
| 18 Apr 2024 | Lung Cancer Edition: Top Headlines for Week of April 15, 2024 | 00:12:10 | |
In this edition, durvalumab improves survival in limited-stage small cell lung cancer, most adults do not test homes for radon exposure and more. Durvalumab improves survival in limited-stage small cell lung cancer Survey: Most adults do not test homes for radon exposure, unconcerned about risks FDA fast tracks investigational bispecific therapy for aggressive lung cancer Research shows complexity of shared decision-making about lung cancer screening Keytruda-Lynparza combination misses survival targets in phase 3 lung cancer trial References: | |||
| 09 Feb 2023 | Lung Cancer Edition: Top Headlines for Week of February 6, 2023 | 00:11:10 | |
In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more. Lobectomy alternatives show varying adverse event profiles in early-stage lung cancer More frequent CT scans not linked to better outcomes after lung cancer surgery Osimertinib-related pneumonitis incidence higher in real-world lung cancer population FDA approves adjuvant Keytruda for non-small cell lung cancer Tarlatamab active in recurrent small cell lung cancer References: Heiden BT, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djac208. Paz-Ares L, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02823. Sato Y, et al. CHEST. 2022;doi:10.1016/j.chest.2022.05.035. Wang Q, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202203-275OC. | |||
| 13 Jul 2023 | Dermatology Edition: Top Headlines for Week of July 10, 2023 | 00:12:34 | |
In this edition, novel serum improves hair growth in androgenetic alopecia; cardiovascular disease linked to dermatological inflammatory diseases; sugary drinks may be associated with male pattern hair loss and more. Novel serum improves hair growth in androgenetic alopecia with no side effects Cardiovascular disease associated with four dermatological inflammatory diseases Consumption of sugary drinks may be associated with male pattern hair loss Researchers advocate for promotion of skin self-examination for early melanoma detection Plaque psoriasis oral therapy moves to phase 3 trial, being tested in other conditions References: Ingrassia JP, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.05.098. Pagan AD, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7424. | |||
| 08 Sep 2022 | Neurology Edition: Top Headlines for Week of September 5, 2022 | 00:09:33 | |
In this edition, blood-based concussion diagnostic tool gets patent; examining the brain’s electrical signals may be key to treating epilepsy, schizophrenia; machine-learning model may predict best antiseizure medications and more. Read the full coverage here: Neurolytixs secures US patent for blood-based concussion diagnostic tool Examination of brain’s electrical signals may be key to treating epilepsy, schizophrenia Machine-learning model may predict which antiseizure medications work best Rafa receives FDA approval for autoinjector to treat status epilepticus in adults Aptinyx completes enrollment of phase 2 trial for oral cognitive impairment treatment References: Hakeem H, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2514. | |||
| 01 Sep 2023 | Prostate Cancer Edition: Top Headlines for Week of August 28, 2023 | 00:13:54 | |
In this edition, ‘equitable access’ to care may reduce racial disparities in survival; exercise may improve sexual function among men with prostate cancer; image-guided adaptive prostate radiation therapy for short-term toxicities, and more. Read the full coverage here: ‘Equitable access’ to care may reduce racial disparities in prostate cancer survival Exercise may improve sexual function among men with prostate cancer Image-guided adaptive prostate radiation therapy reduces risk for short-term toxicities Recent developments in advanced prostate cancer space pave way for future breakthroughs Radiation plus intensive systemic therapy improves outcomes in prostate cancer subset References: Bossi A, et al. Abstract LBA5000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Galvao DA, et al. Abstract 71. Presented at: ASCO Breakthrough; Aug. 3-5, 2023; Yokohama. Leeman JE, et al. Cancer.2023;doi:10.1002/cncr.34836. Sayegh N, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.26546. Sharifi N, et al. J Clin Oncol. 2023;doi:10.1200/JCO.2022.40.16_suppl.5022. | |||
| 23 Mar 2023 | Neurology Edition: Top Headlines for Week of March 20, 2023 | 00:09:12 | |
In this edition, FDA clears lab blood test for evaluating concussion, marriage linked to lower risk for dementia, FDA approves nasal spray for migraine in adults and more. Read the full coverage here: FDA clears lab blood test for evaluating concussion Marriage linked to lower risk for dementia, mild cognitive impairment FDA approves nasal spray for migraine in adults Noninvasive device for treating tinnitus receives FDA de novo approval Differences in fighter pilots’ brain connectivity may have implications for space travel References: Radstake WE, et al. Front Physiol. 2023;doi:10.3389/fphys.2023.1082166. Skirbekk V, et al. J Aging Health. 2023;doi:10.1177/08982643221131926. | |||
| 17 Nov 2022 | Neurology Edition: Top Headlines for Week of November 14, 2022 | 00:08:27 | |
In this edition, neurologic effects of COVID-19 among pediatric populations, FDA accepts NDA for extended-release carbidopa/levodopa, antihistamines could be promising therapy for Parkinson’s disease and more. Read the full coverage here: Neurologic effects of COVID-19 persisted among pediatric populations in 2021 FDA accepts NDA for extended-release carbidopa/levodopa Parkinson’s treatment Antihistamines could be promising adjuvant therapy for Parkinson’s disease Recurrent head injury linked to affective dysregulation, impulse control AI-powered detection tool found 85% of aneurysms were not referred for follow-up References: LaRovere KL, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3881. Richey LN, et al. M240. Associations of prior head injury with mild behavioral impairment domains. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago. Tandra G, et al. M189. Literature-based discovery to assess Parkinson’s disease adjuvants to levodopa. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago. | |||
| 21 Sep 2023 | Dermatology Edition: Top Headlines for Week of September 18, 2023 | 00:12:36 | |
In this edition, CDC issues a health advisory concerning flesh-eating bacterium, staging for melanoma does not represent accurate recurrence and mortality and more. CDC issues health advisory about recent reports of fatal Vibrio vulnificus Study finds melanoma treatment costs have increased, but so has survival Melanoma staging system inaccurately reflects recurrence, mortality risk Study: Nemolizumab shows promise as prurigo nodularis treatment Adverse events after ICI treatment linked to improved outcomes in patients with melanoma References: Bateni SB, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3179. Deng J, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.2609. Du Y, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3003. Helvind NM, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3256. | |||
| 13 Dec 2022 | Breast Cancer Edition: Top Headlines for Week of December 12, 2022 | 00:10:19 | |
In this episode, FDA grants fast track designation to REM-001; practice-changing treatment advances continue; proton partial breast radiotherapy appears effective and more. Read the full coverage here: FDA grants fast track designation to REM-001 for cutaneous metastatic breast cancer Practice-changing treatment advances continue in early-stage triple-negative breast cancer Proton partial breast radiotherapy appears effective, safe for early breast cancer New endocrine therapy options for patients with breast cancer on the horizon, expert says Use of contraception decreases after breast cancer diagnosis References: Choi JI, et al. Clin Transl Radiat Oncol. 2022;doi:10.1016/j.ctro.2022.08.013 Healio Interviews Lambertini M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetowrkopen.2022.33137. Traina TA, et al. Early-stage triple-negative breast cancer. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022. | |||
| 18 Aug 2022 | Neurology Edition: Top Headlines for Week of August 15, 2022 | 00:10:45 | |
In this edition, light stimulation may help delay Alzheimer’s progression; sleep EEGs may predict future disease and mortality; updated data on the prevalence of tinnitus and more. Read the full coverage here: Light stimulation may help delay AD progression, more research needed in older adults Sleep EEGs may predict future disease, mortality Tinnitus affects more than 740 million adults globally Gut-based neurotoxin triggers inflammation associated with Alzheimer's disease CSF biomarkers support AD diagnosis in nearly 90% of clinical cases References: Agüero P, et al. CSF Alzheimer’s biomarkers in clinical practice. Presented at: Alzheimer’s Association International Conference; July 31-Aug. 4; San Diego. Beckers E, et al. Characterization of pupillary responses to alternating blue and orange light exposures in a fMRI protocol. Presented at: Alzheimer’s Association International Conference; July 31-Aug. 4; San Diego. Jarach CM, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2189. Pogue AI, et al. Front Neurol. 2022;doi:10.3389/fneur.2022.900.048 Sun H, et al. Predicting incident outcomes from the microstructure of sleep. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C. | |||
| 21 Apr 2022 | Neurology Edition: Top Headlines for Week of April 18, 2022 | 00:08:37 | |
In this week’s edition, the FDA approval of an oral anticonvulsant; plus news you may have missed from the AAN and ACTRIMS meetings. Read the full coverage here: FDA approves oral anticonvulsant New drug improved tic severity in children with Tourette syndrome Vitamin D levels not associated with adverse outcomes in European MS patients Zolpidem may be effective for prolonged disorders of consciousness Amygdala overgrowth begins in first year of life in infants with ASD References: Gilbert DL, et al. ES1.002: Ecopipam in children and adolescents with Tourette syndrome: Results from a randomized, double-blind, placebo-controlled phase 2b study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. Vasileiou E, et al. Vitamin D polygenic score and multiple sclerosis outcomes. Presented at: ACTRIMS Forum; Feb. 24-26; West Palm Beach, Florida. Cassidy J, et al. Impact of zolpidem in the treatment of prolonged disorders of consciousness. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. Shen MD, et al. Am J Psychiatry. 2022;doi:10.1176/appi.ajp.21090896 Disclosures: Please see each study for relevant financial disclosures. | |||
| 06 Apr 2023 | Lung Cancer Edition: Top Headlines for Week of April 3, 2023 | 00:11:59 | |
In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more. Read the full coverage here: Study reveals ‘paradigm shift’ in non-small cell lung cancer during past decade Osimertinib extends survival in early EGFR-mutated non-small cell lung cancer Amivantamab-vmjw shows durable activity in subgroup of patients with advanced NSCLC Patients with small cell lung cancer have ‘real choice’ in radiotherapy regimen Pembrolizumab regimen extends OS in advanced malignant pleural mesothelioma References: Bogart J, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.01359. Chi SA, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2002. Press Release | |||
| 10 Oct 2023 | Prostate Cancer Edition: Top Headlines for Week of October 9, 2023 | 00:13:40 | |
In this edition, precision navigators reduce racial disparities in genomic testing; cancer diagnoses fell sharply during early days of pandemic; Prostate Cancer Awareness Month updates, and more. Read the full coverage here: Precision navigators reduce racial disparities in genomic testing for prostate cancer Cancer diagnoses fell sharply during early days of pandemic, NCI report shows Prostate Cancer Awareness Month: Financial hardship common, exercise beneficial Researchers identify 11 genes linked to aggressive prostate cancer Black men less likely to receive targeted therapy for metastatic prostate cancer References: Allen AJ, et al. Abstract 122. Presented at: ASTRO Annual Meeting; Oct. 1-4, 2023; San Diego. | |||
| 10 Nov 2022 | Neurology Edition: Top Headlines for Week of November 7, 2022 | 00:11:32 | |
In this edition, we bring you more news and Healio-exclusive interviews from the American Neurological Association Annual Meeting. Read the full coverage here: Diversity key to understanding genetics of neurodegenerative disease Assessing chemical exposures key to understanding neuro diseases and disorders VIDEO: Neurological complications can spur from certain infectious diseases Age, specific pathology tied to shorter symptom duration in rapidly progressive dementia Cognition in persons with epilepsy dependent on type, therapy model References: Asghar F et al. Cognition in persons with epilepsy: Differences based on disease type and therapy. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago. Cory-Slechta DA. Chemical exposures: The ignored environmental risk factors for neurodegenerative diseases and neurodevelopmental disorders. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago. Guerreiro R. The genetics of neurodegenerative diseases: from rare populations to common variants. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago. Lazar E, et al. Dissecting the neuropathological contributors to rapidly progressive dementia. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago. Saylor D, et al. A string of pearls: Key considerations in the care of neurological infections. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago. | |||
| 13 Oct 2022 | Neurology Edition: Top Headlines for Week of October 10, 2022 | 00:14:22 | |
In this edition, preventive therapies should be offered for migraines; targeting neuropathic symptoms for poststroke pain; PDE5 inhibitors not associated with lower AD, dementia risk and more. Read the full coverage here: Range of preventive therapies should be offered for migraines Poststroke pain may be controlled by targeting neuropathic symptoms Treatment with PDE5 inhibitors not associated with reduced risk for AD, dementia NFL, NFLPA finalize review of updated concussion protocol in wake of Tagovailoa injury Blunt cerebrovascular injury increases risk for ischemic stroke, requires rapid response References: Bottros M. Poststroke pain: What it is, what causes it and how to treat it. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas. Desai RJ, et al. Brain Commun. 2022;doi:10.1093/braincomms/fcac247. Diamond M. Diamond Headache Clinic migraine track: Prevention, treatment. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas. Stone DK. Head and neck injury: Predictors of ischemic stroke. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas. | |||
| 16 Nov 2023 | Dermatology Edition: Top Headlines for Week of November 13, 2023 | 00:07:52 | |
In this edition, dermatologists ‘uniquely positioned’ to aid human trafficking victims; FDA approves Cosentyx for hidradenitis suppurativa and more. Dermatologists ‘uniquely positioned’ to recognize, aid human trafficking victims FDA approves Cosentyx as first IL-17A inhibitor for hidradenitis suppurativa FDA approves Stelara biosimilar for treatment of psoriasis, multiple inflammatory diseases RECELL system efficacious in vitiligo repigmentation Isotretinoin efficacious in seborrheic dermatitis treatment References: Elbuluk N. Optimizing melanocyte cell transplant procedure for treatment of vitiligo. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago. Kourosh S. The role of dermatologic surgeons in advocating for those affected by human trafficking. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago. | |||
| 15 Sep 2022 | Neurology Edition: Top Headlines for Week of September 12, 2022 | 00:12:15 | |
In this edition, new cannabinoids hold promise for medical applications; Theranica secures $45 million for migraine treatment device and more. Read the full coverage here: Newly discovered cannabinoids hold promise for medical, pain applications Theranica secures $45 million to expand wearable migraine treatment device in US Implantable loop recorder screening for AF not linked to stroke reduction risk Survey shows OTC pain relievers remain ‘common, valuable’ Amneal submits new drug application for extended-release Parkinson’s treatment References: Diederichsen SZ et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3031. Guglieri M et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2480. Jacknin J. How green is my valley: Newly discovered cannabinoids and their possible medical uses. Presented at: PAINWeek; Las Vegas; Sept. 6-9, 2022. | |||
| 04 May 2023 | Leukemia Edition: Top Headlines for Week of May 1, 2023 | 00:12:33 | |
In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more. Addition of immunotherapy to chemotherapy improves survival rates of infants with leukemia Extreme poverty linked to nearly twofold higher risk for relapse among children with ALL FDA approves allogeneic cell therapy Omisirge for patients with blood cancers Vaping linked to cancer-related cognitive impairment among young adult cancer survivors Intervention reduces financial toxicity among people with blood cancers References: Healio Interview Ng DQ, et al. JCO Oncol Pract. 2023;doi:10.1200/op.22.00458. van der Sluis IM, et al. N Eng J Med. 2023;doi:10.1056/NEJMoa2214171. | |||
| 06 Jun 2024 | DME/Retina Edition: Top Headlines for Week of June 3, 2024 | 00:10:27 | |
In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME Phase 2 study of potential DME oral therapy meets primary endpoints FDA approves aflibercept biosimilars Yesafili, Opuviz References: Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle. Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina. | |||
| 27 Apr 2022 | AMD/Retina Edition: Top Headlines for Week of April 25, 2022 | 00:07:19 | |
In this edition, European commission approves Beovu for DME, choroidal vascularity index linked with geographic atrophy progression, intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy, and more. Read the full coverage here: Susvimo noninferior to monthly ranibizumab with similar efficacy European Commission approves Beovu for DME Intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy Teprotumumab may provide better outcomes than IV methylprednisolone in thyroid eye disease Choroidal vascularity index linked with geographic atrophy progression References: Healio Interviews Holekamp NM, et al. Ophthalmology. 2022;doi:10.1016/j.ophtha.2021.09.016. Newman N, et al. The Phase III REFLECT Trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON). Presented at: American Academy of Neurology Annual Meeting; April 2-7, 2022; Seattle. Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305. | |||
| 09 May 2024 | DME/Retina Edition: Top Headlines for Week of May 6, 2024 | 00:09:54 | |
In this edition, FDA accepts new drug application for Eluminex, most mentors in vitreoretinal subspecialty are men and more. FDA accepts investigational new drug application for Eluminex DME treatment Most mentors in vitreoretinal subspecialty are men Carotid artery stenosis linked to retinal changes in patients with diabetic retinopathy AI-assisted technology makes retinal imaging 100 times faster, with greater contrast FDA clears fully autonomous AI for portable diabetic retinopathy screening References: Das V, et al. Commun Med. 2024;doi:10.1038/s43856-024-00483-1. Lee CY, et al. BMC Ophthalmol. 2024;doi:10.1186/s12886-024-03391-z. Shah SM, et al. Demographics and productivity trends among academically affiliated female vitreoretinal specialists in the United States. Presented at: Real World Ophthalmology; April 27, 2024 (virtual meeting). | |||
| 09 Sep 2022 | Breast Cancer Edition: Top Headlines for Week of September 5, 2022 | 00:11:39 | |
In this episode, VTE rate with abemaciclib (uh-bem-uh-cy-clib) higher in real-world setting; Enhertu extends progression-free survival in patient subgroup; FDA grants priority review to elacestrant (ee-las-cess-trant) for metastatic disease; and more. Read the full coverage here: VTE rate with abemaciclib higher in real-world setting among patients with breast cancer Enhertu extends progression-free survival in breast cancer subgroup, topline data show FDA grants priority review to elacestrant for metastatic breast cancer Lack of financial comfort linked to weight gain among young breast cancer survivors Hispanic ethnicity often not reported in breast cancer studies References: Bazan JG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.3527. | |||
| 11 Apr 2024 | DME/Retina Edition: Top Headlines for Week of April 8, 2024 | 00:12:28 | |
In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more. PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME Early safety, efficacy results positive for Restoret in DME, wet AMD References: Chin Yee DS, et al. Outcomes in eyes requiring IOP-lowering surgery after treatment with the 0.19-mg fluocinolone acetonide implant for DME: The PALADIN study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco. Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii. Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii. | |||
| 06 Jul 2023 | Leukemia Edition: Top Headlines for Week of July 3, 2023 | 00:12:35 | |
In this edition, CAR-T trial for leukemia paused after patient death; obesity may increase risk for blood cancer; new CAR T-cell therapies ‘waiting’ for patients with leukemia and more. Seattle Children’s pauses trial of CAR-T for leukemia after patient death Obesity may increase risk for blood cancer VIDEO: New CAR T-cell therapies ‘waiting in the wings’ for patients with leukemia VIDEO: Jaktinib shows promise in treatment of myelofibrosis Venetoclax regimen not superior to standard therapy alone for older patients with CLL References: ASCO Annual Meeting ASCO Annual Meeting | |||
| 09 Mar 2023 | Lung Cancer Edition: Top Headlines for Week of March 6, 2023 | 00:10:44 | |
In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more. Read the full coverage here: Neoadjuvant nivolumab confers durable survival benefit in resectable NSCLC Global economic cost of cancer estimated to exceed $25 trillion over 30 years Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints Researchers develop AI model to accelerate radiation therapy planning for lung cancer Asian, Black patients with lung cancer face longer wait times to radiation treatment References: Chen S, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.7826. Hosny A, et al. Lancet Digit Health. 2022;doi:10.1016/S2589-7500(22)00129-7. Press Release Rekulapelli A, et al. Health Equity. 2022;doi:10.1089/heq.2022.0104 Rosner S, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2994. | |||
| 11 Aug 2022 | Neurology Edition: Top Headlines for Week of August 8, 2022 | 00:09:42 | |
In this edition, physicians should question patients with restless leg syndrome about cannabis use ; digital therapeutic improves symptoms of insomnia, anxiety and depression; more efficient sleep may benefit patients with fibromyalgia and insomnia and more. Read the full coverage here: Physicians should question patients with restless leg syndrome about cannabis use Digital therapeutic improves symptoms of insomnia, anxiety, depression for 6 months More efficient sleep may benefit patients with fibromyalgia, insomnia FDA accepts new drug application, grants priority review for ALS treatment Quanterix announces validation of biomarker detection test to aid in diagnosis of AD References: Kachechian T, et al. Prevalence of cannabis use in patients with restless leg syndrome for symptomatic relief. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C. Nair N, et al. Effect of sleep on the relationship between pain-related disability and neural correlates of pain processing in adults with fibromyalgia and insomnia. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C. | |||
| 01 Sep 2022 | Neurology Edition: Top Headlines for Week of August 29, 2022 | 00:12:33 | |
In this edition, BMI is associated with dementia in women and linked with disease in men; Healthy diet, physical activity are linked to lower mortality in adults with PD; mild TBI and CT scans and more. Read the full coverage here: High BMI negatively associated with dementia in women, low BMI linked with disease in men Healthy diet, physical activity linked to lower mortality rate in adults with PD Patients with mild TBI, negative CT scan should be evaluated 2 weeks after injury FDA approves spinal cord stimulation system for broad treatment of chronic pain Artificial intelligence model detects Parkinson’s disease via nocturnal breathing signals References: Jacob L, et al. J Alzheimers Dis. 2022;doi:10.3233/JAD-220147. Madhok DY, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.23245. Yang Y, et al. Nat Med. 2022;doi:10.1038/s41591-022-01932-x. Zhang X et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.27738. | |||
| 20 Oct 2022 | Neurology Edition: Top Headlines for Week of October 17, 2022 | 00:11:07 | |
In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more. Read the full coverage here: COVID-19 patients at risk for neurological complications 1 year post-infection Patients with back pain benefited from at-home VR program FDA requests further analysis of Supernus Parkinson’s treatment Erenumab not effective at reducing pain in trigeminal neuralgia Multiple factors indicate need for additional care after concussion References: Andersen ASS, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00294-0. Hou BQ, et al. Clin J Sport Med. 2022;doi:10.1097/JSM.0000000000001057. Maddox T, et al. At-home virtual reality program for chronic low back pain: Durability of a randomized, placebo-controlled trial to 18-months post-treatment. Presented at: PAINWeek; Las Vegas; Sept. 6-9, 2022. | |||
| 11 Nov 2022 | Breast Cancer Edition: Top Headlines for Week of November 7, 2022 | 00:13:07 | |
In this episode, data show ‘critical need’ for universal genetic testing; patients with inflammatory breast cancer at high risk for brain metastases; palbociclib fails to benefit breast cancer subgroup and more. Read the full coverage here: Data show ‘critical need’ for universal genetic testing of patients with breast cancer Patients with inflammatory breast cancer at high risk for brain metastases Palbociclib fails to benefit breast cancer subgroup, yielding lessons for future research Low-dose aspirin does not reduce breast cancer risk Interventions improve cancer screening rates among women in rural areas References: Cairat M, et al. Abstract 1840. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva. DeMichele A, et al. Adjuvant palbociclib for ER+ breast cancer (PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort. Presented at: ASCO Plenary Series; Oct. 18, 2022. Paskett ED, et al. Abstract 1959. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva. Warren LEG, et al. Cancer. 2022;doi:10.1002/cncr.34441. Whitworth PW, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32787. | |||
| 12 Sep 2024 | DME/Retina Edition: Top Headlines for Week of September 9, 2024 | 00:08:40 | |
In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more. Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema OCT, visual acuity popular benchmarks in clinical practice guidelines for DME First patient dosed in phase 2 trial of EC-104 implant for diabetic macular edema OCS-01 eye drop for DME in second stage of phase 3 trial Q&A: Susvimo delivers immediate durability after implantation in wet AMD References: Crawford C. Update on OCS-01: A novel topical drop for DME in phase 3 trials. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah. Healio Interviews McAllister M, et al. Assessing the strength of clinical practice guidelines for managing diabetic macular edema — A systematic literature review. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm. | |||
| 20 Jul 2023 | Leukemia Edition: Top Headlines for Week of July 17, 2023 | 00:11:56 | |
In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more. Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia Pirtobrutinib produces high response rates in heavily pretreated CLL, SLL CDC study reveals overall increase in pediatric cancer incidence over 16 years Cancers with high incidence among racial/ethnic minorities receive less research funding Women more likely to experience severe toxicity from cancer treatment References: Haghighat S, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad097. Mato AR, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2300696. Shimony S, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2023009976. Siegel DA, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad115. Unger JM, et al. Abstract SY43-03. Presented at American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando. | |||